Metronidazolo B. Braun

Metronidazole, the active ingredient in Metronidazolo B. Braun, is a nitroimidazole antibiotic presented as an intravenous solution for intravenous administration. It is indicated for the treatment of anaerobic bacterial infections, intra‑abdominal infections, bacterial vaginosis, and certain protozoal infections such as trichomoniasis in adult patients.

GNH USA supplies Metronidazolo B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for global distribution.

Metronidazole is a nitroimidazole antibiotic used to treat infections caused by anaerobic bacteria and certain protozoa. - Anaerobic bacterial infections: eradicates infection by targeting anaerobic organisms in tissues. - Intra‑abdominal infections: helps resolve peritonitis and abscesses caused by susceptible anaerobes. - Bacterial vaginosis: restores normal vaginal flora by eliminating Gardnerella species. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms of the protozoal infection.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Metallic taste: transient metallic sensation in the mouth. - Headache: mild to moderate headache. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Seizures: rare neurologic events, especially with high doses. - Peripheral neuropathy: tingling or numbness in extremities. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Hepatotoxicity: elevated liver enzymes or liver injury.

When using Metronidazole, clinicians should consider several safety precautions to minimize risks. - Pregnancy: use only if benefits outweigh risks, as safety data are limited. - Alcohol interaction: avoid alcohol during treatment and for at least 48 hours after, to prevent disulfiram‑like reaction. - Renal impairment: adjust therapy in patients with severe renal dysfunction. - Neurologic symptoms: monitor for signs of seizures or peripheral neuropathy. - Store at room temperature: keep the solution in original container, protect from light and freeze.

Metronidazole can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, nausea (disulfiram‑like reaction). - Warfarin: can potentiate anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Phenytoin: may reduce metronidazole levels, decreasing effectiveness. - Oral contraceptives: may reduce contraceptive efficacy; advise additional barrier methods.